Summary
This prediction ended on 30.03.20 with a price of €8.23. Massive losses of -61.90% were the result for the BUY prediction by melinda. melinda has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Adocia | -10.979% | -10.979% | 2.215% | 43.541% |
| iShares Core DAX® | 3.002% | 4.755% | 23.700% | 68.627% |
| iShares Nasdaq 100 | 2.966% | 0.363% | 8.027% | 116.238% |
| iShares Nikkei 225® | 5.606% | 4.528% | 20.313% | 56.217% |
| iShares S&P 500 | 2.312% | 1.811% | 5.451% | 70.924% |
According to melinda what are the pros and cons of Adocia for the foreseeable future?
Pros
Could be worthwhile Investment >10% per year
Cons
Comments by melinda for this prediction
In the thread Adocia diskutieren
Secteur Recherche biotechnologique et médicale Agenda 17/07 Publication de résultats
Le CA par type de revenus se ventile entre revenus issus de contrats de recherche et de collaboration (96,7%) et revenus de licences (3,3%).
A fin 2017, Adocia dispose d'un portefeuille de 4 produits en phase I/II de développement clinique (BioChaperone Lispro U100 et U200, BioChaperone Combo et HinsBet U100) et de 6 produits en développement préclinique (HinsBet U500, BioChaperone Glucagon, BioChaperone Glargine Dulaglutide, BioChaperone Glargine Liraglutide, BioChaperone Lispro Pramlintide et BioChaperone Lispro Exenatide).
Nombre d'employés
: 129 personnes.